Benzinga | May 6, 2021 05:38PM EDT

Nektar Therapeutics Q1 EPS $(0.68) Beats $(0.72) Estimate, Sales $23.60M Miss $26.90M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.72) by 5.56 percent. This is a 28.3 percent decrease over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $23.60 million which missed the analyst consensus estimate of $26.90 million by 12.27 percent. This is a 53.33 percent decrease over sales of $50.57 million the same period last year.